admin – page 8 – eisai china lnc.-威尼斯人888

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that three oral presentations and eight poster presentations, highlighting the latest data on its alzheimer’s disease / dementia pipeline including anti-amyloid beta (aβ) protofibril antibody ban2401, orexin receptor antagonist lemborexant and a simple blood diagnostic for alzheimer’s disease (ad), will be given at the 12th clinical trials on alzheimer’s disease (ctad) conference taking place in san diego, california in the united states, from december 4 to 7, 2019. ban2401 is being jointly developed by eisai and biogen inc.

eisai china inc. is certified as the “top employers china 2020” with its outstanding performance announced by the top employers institute on december 2, 2019.

mr. yamada koki, deputy general manager of eisai (china) pharmaceutical co., ltd. (hereinafter referred to as “eisai china”), attended the 2018-2019 annual awards ceremony for advanced collectives and outstanding individuals in peking university health science center, on behalf of eisai china, on november 26, 2019. a total of 40 students won the eisai china scholarships for their outstanding performance, and 10 students got the eisai china grants during this academic year. eisai china has awarded scholarships and grants to outstanding students at peking university health science center for 8 consecutive years.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has entered into an agreement to transfer the rights to receive royalties on the sales outside of japan for an investigational anti-cancer agent tazemetostat (generic name) to royalty pharma (headquarters: new york, united states).

on october 19, 2019, the “2019 ads beijing” sponsored by eisai china inc. was held in beijing, which is another platform for doctors’ information exchanges. featuring the theme of “let’s build hope together”, the main forum and three sub-forums focused on the latest cutting-edge academic research and clinical practice and development in china and in the world. 37 well-known experts and scholars from china, japan, singapore, spain and other countries, more than 300 on-site guests and nearly 1,000 on-line guests jointly discussed and conducted dialogues and interactions, producing collision of ideas and academic resonance between china and foreign countries.